Respiratory Medicine, Institute of Infection, Immunity & Inflammation, University of Glasgow and Gartnavel General Hospital, Glasgow, G12 OYN Scotland, United Kingdom.
J Allergy Clin Immunol. 2012 Mar;129(3):655-663.e8. doi: 10.1016/j.jaci.2011.12.996. Epub 2012 Feb 2.
Matrix metalloproteinase (MMP)-12 has been implicated in the pathogenesis of both chronic obstructive pulmonary disease (COPD) and asthma. The influence of disease severity on sputum MMP-12 concentrations and activity is not known.
We sought to examine the relationship between disease severity assessed by means of lung function and computed tomography (CT) and induced sputum MMP-12 concentrations and activity in patients with asthma and COPD.
In 208 subjects (109 asthmatic patients, smokers and never smokers, mild, moderate, and severe; 53 patients with COPD, smokers and exsmokers, mild, moderate, and severe; and 46 healthy control subjects, smokers and never smokers), we measured induced sputum MMP-12 concentrations (ELISA) and enzyme activity (fluorescence resonance energy transfer), sputum cell MMP12 mRNA expression (quantitative PCR [qPCR]), diffusing capacity for carbon monoxide (Dlco), and CT assessment of emphysema (percentage of low-attenuation areas at less -950 Hounsfield units).
Sputum MMP-12 concentrations are greater in patients with COPD and smokers with asthma than in healthy nonsmokers (P = .003 and P = .035, respectively) but similar to those seen in healthy smokers. In patients with COPD, disease severity, when measured by means of CT-assessed emphysema, but not by means of spirometry or Dlco values, is directly associated with sputum MMP-12 concentrations and activity. In the asthma groups there is no significant association between disease severity and sputum MMP-12 concentrations or activity.
Sputum MMP-12 concentrations and activity in patients with COPD are directly associated with the extent of emphysema measured by means of CT. This finding supports a role for MMP-12 in the pathogenesis of COPD and might suggest that blocking MMP-12 activity in patients with COPD could prevent the further development of emphysema.
基质金属蛋白酶-12(MMP-12)与慢性阻塞性肺疾病(COPD)和哮喘的发病机制有关。目前尚不清楚疾病严重程度对痰中 MMP-12 浓度和活性的影响。
我们旨在研究通过肺功能和计算机断层扫描(CT)评估的疾病严重程度与哮喘和 COPD 患者痰中 MMP-12 浓度和活性之间的关系。
在 208 名受试者(109 例哮喘患者,包括吸烟者和不吸烟者,轻度、中度和重度;53 例 COPD 患者,包括吸烟者和戒烟者,轻度、中度和重度;和 46 例健康对照者,包括吸烟者和不吸烟者)中,我们测量了诱导痰 MMP-12 浓度(ELISA)和酶活性(荧光共振能量转移)、痰细胞 MMP12mRNA 表达(定量 PCR [qPCR])、一氧化碳弥散量(Dlco)和 CT 评估的肺气肿(低于-950 豪斯菲尔德单位的低衰减区域百分比)。
与健康不吸烟者相比,COPD 患者和哮喘吸烟者的痰 MMP-12 浓度更高(P=0.003 和 P=0.035),但与健康吸烟者相似。在 COPD 患者中,通过 CT 评估的肺气肿,而不是通过肺功能或 Dlco 值来衡量的疾病严重程度与痰 MMP-12 浓度和活性直接相关。在哮喘组中,疾病严重程度与痰 MMP-12 浓度或活性之间没有显著关联。
COPD 患者的痰 MMP-12 浓度和活性与 CT 测量的肺气肿程度直接相关。这一发现支持 MMP-12 在 COPD 发病机制中的作用,并可能表明在 COPD 患者中阻断 MMP-12 活性可能阻止肺气肿的进一步发展。